RPA2 (Ab-21) Antibody

What is RPA2 and what role does it play in DNA metabolism?

RPA2 (Replication Protein A 32 kDa subunit, also known as RPA p34) is one of three subunits comprising the RPA heterotrimer complex, functioning alongside the 70 kDa RPA1 and 14 kDa RPA3 subunits. The protein contains approximately 270 amino acids with distinct functional domains: a glycine/serine-rich N-terminus (amino acids 1-33), a DNA-binding domain (amino acids 43-171), and a protein interaction C-terminus (amino acids 187-270). RPA2 plays essential roles in multiple DNA metabolic processes including replication, recombination, and repair mechanisms . The RPA complex binds and stabilizes single-stranded DNA (ssDNA) intermediates formed during DNA replication or upon DNA stress, preventing their reannealing while simultaneously recruiting various proteins involved in DNA metabolism . This functionality makes RPA2 crucial for both normal DNA replication and cellular responses to DNA damage events. Multiple splice variants of RPA2 exist, including versions with N-terminal extensions, further diversifying its functional capabilities in different cellular contexts .

What is the significance of RPA2 phosphorylation at threonine 21?

Phosphorylation of RPA2 at threonine 21 (T21) represents a critical post-translational modification that occurs primarily in response to replication stress and DNA damage. This specific phosphorylation event, along with phosphorylation at serines 4, 8, 23, 29, and 33, regulates RPA complex interactions with DNA repair and replication proteins . T21 phosphorylation serves as a molecular switch that modulates RPA2's functions during cellular stress responses. When RPA2 becomes hyperphosphorylated (including at T21) following treatments with agents like hydroxyurea (HU) or camptothecin, it associates with single-stranded DNA and the recombinase protein Rad51, facilitating homologous recombination repair processes . Phospho-RPA2-T21 occurs predominantly during late S and G2 phases of the cell cycle, consistent with its role in regulating homologous recombination, which is a major repair mechanism during these phases . This phosphorylation provides a reliable marker for ongoing replication stress in both experimental settings and clinical samples.

How can I distinguish between different phosphorylation states of RPA2?

The phosphorylation status of RPA2 can be distinguished using phospho-specific antibodies combined with techniques like western blotting, immunofluorescence, and flow cytometry. For T21 phosphorylation specifically, commercially available antibodies like AF6654 and EPR2846(2) have been validated for detecting this modification . In western blot analysis, hyperphosphorylated RPA2 typically appears as a band of approximately 40 kDa, with shifted mobility compared to the unphosphorylated form . When using immunofluorescence, phospho-RPA2-T21 appears as discrete nuclear foci. The intensity and number of these foci correlate with the degree of replication stress, allowing for quantitative assessment through foci counting (with ≥5 foci per cell often used as a threshold for positive scoring) . Different phosphorylation states can be induced experimentally using various DNA-damaging agents: hydroxyurea and thymidine primarily induce replication stress-associated phosphorylation, while ionizing radiation can generate direct DNA double-strand breaks with different phosphorylation patterns . When analyzing clinical or experimental samples, it's advisable to include appropriate positive controls (e.g., cells treated with replication stress inducers) and negative controls (e.g., RPA2 knockdown samples) to validate antibody specificity .

How can I validate the specificity of phospho-RPA2-T21 antibodies?

Validating the specificity of phospho-RPA2-T21 antibodies is crucial for ensuring reliable experimental results. A comprehensive validation approach includes several key steps: First, perform siRNA knockdown of RPA2 as a negative control – cells with reduced RPA2 expression should show significantly diminished phospho-RPA2-T21 signal in both untreated and hydroxyurea-treated conditions . Second, compare signal intensity in untreated versus replication stress-induced conditions (e.g., hydroxyurea treatment) – a specific antibody will show dose-dependent increases in signal with increasing replication stress . Third, utilize phosphatase treatment of cell lysates prior to immunoblotting – this treatment should eliminate the phospho-specific signal if the antibody is truly phospho-specific. Fourth, use peptide competition assays with phosphorylated and non-phosphorylated peptides corresponding to the T21 region – the phosphorylated peptide should competitively diminish antibody binding while the non-phosphorylated version should not. Finally, confirm specificity through immunofluorescence by co-staining with antibodies against other replication stress markers (e.g., γH2AX) and observing appropriate co-localization patterns. Researchers have validated the sensitivity and specificity of phospho-RPA2-T21 antibodies in both cell culture systems and formalin-fixed paraffin-embedded (FFPE) tumor samples, confirming that pRPA2 foci staining accurately reflects replication stress across different experimental conditions .

What controls should be included when using phospho-RPA2-T21 in immunofluorescence studies?

When conducting immunofluorescence studies with phospho-RPA2-T21 antibodies, include these essential controls: First, prepare positive controls using cells treated with replication stress inducers such as hydroxyurea, which should exhibit increased nuclear phospho-RPA2-T21 foci formation . Second, include negative controls using RPA2 knockdown samples to confirm antibody specificity – these samples should show significantly reduced phospho-RPA2-T21 signal even after hydroxyurea treatment . Third, include untreated wild-type cells as baseline controls to establish normal levels of endogenous phosphorylation. Fourth, when scoring phospho-RPA2-T21 foci, analyze more than 100 cells per sample to account for potential heterogeneity, with a common threshold being ≥5 foci per cell for positive scoring . Fifth, include co-staining with DAPI or another nuclear marker to confirm nuclear localization, and consider co-staining with cell cycle markers (e.g., PCNA, Cyclin B) to correlate phospho-RPA2-T21 patterns with specific cell cycle phases. Sixth, when working with FFPE samples, validate fixation protocols by comparing fresh and fixed samples from the same experimental conditions to ensure comparable staining patterns. Researchers have successfully established the reliability of phospho-RPA2-T21 immunofluorescence in both cell culture systems and FFPE tumor samples, confirming that this approach accurately reflects cellular replication stress status across different experimental conditions .

How does RPA2 hyperphosphorylation affect homologous recombination repair?

RPA2 hyperphosphorylation plays a pivotal role in facilitating homologous recombination (HR) repair, particularly in response to replication stress. Mechanistically, hyperphosphorylated RPA2 associates with single-stranded DNA (ssDNA) and directly interacts with Rad51, a key recombinase protein essential for HR . This phosphorylation-dependent interaction increases the affinity between RPA and Rad51, thereby promoting the displacement of RPA and the subsequent loading of Rad51 onto ssDNA, which initiates the strand invasion step of HR . Experimental evidence demonstrates that cells expressing phosphorylation-defective RPA2 mutants (RPA2-A, where phosphorylation sites including T21 are mutated to alanine) exhibit significant defects in Rad51 foci formation following hydroxyurea treatment . These cells show decreased frequency of HR repair in response to replication arrest but, interestingly, display no obvious defects in ionizing radiation-induced Rad51 recruitment or I-Sce-I-induced HR . Furthermore, the timing of RPA2 hyperphosphorylation, which occurs predominantly in late S and G2 phases where HR is a major repair mechanism, provides additional evidence for its specific role in regulating HR . The functional significance of this regulation is underscored by increased chromosomal abnormalities after hydroxyurea treatment (but not after ionizing radiation) in cells expressing phosphorylation-defective RPA2, indicating that RPA2 hyperphosphorylation is critical for maintaining genomic stability specifically in response to replication arrest .

What is the relationship between RPA2 phosphorylation and cell viability under replication stress?

RPA2 phosphorylation status significantly impacts cell viability under replication stress conditions through several mechanistic pathways. Cells expressing phosphorylation-deficient RPA2 mutants show markedly decreased viability when confronted with replication stress induced by agents like hydroxyurea . This viability deficit stems from the role of RPA2 hyperphosphorylation in promoting homologous recombination (HR)-mediated repair of stalled or collapsed replication forks. Without proper RPA2 phosphorylation, cells exhibit increased chromosomal aberrations following hydroxyurea treatment, indicating compromised genomic stability under replication stress . Interestingly, the same phosphorylation-defective RPA2 cells show similar sensitivity to ionizing radiation as wild-type cells, highlighting the specific role of RPA2 phosphorylation in the cellular response to replication stress rather than direct DNA double-strand breaks . The hyperphosphorylation of RPA2 appears to function as a molecular switch that inhibits DNA replication while simultaneously promoting DNA repair, particularly HR-mediated repair. This dual functionality explains why RPA2 phosphorylation is essential for maintaining cell viability specifically under conditions of replication stress . The clinical relevance of this relationship is evident in tumor samples, where high levels of phospho-RPA2-T21 foci correlate with better patient survival outcomes after platinum chemotherapy, which induces replication stress in cancer cells .

How can I optimize phospho-RPA2-T21 detection in formalin-fixed paraffin-embedded (FFPE) samples?

Optimizing phospho-RPA2-T21 detection in FFPE samples requires careful attention to several methodological factors: First, validate the fixation protocol by comparing cell blocks prepared under controlled conditions – research has demonstrated successful detection of phospho-RPA2 foci in FFPE samples of cancer cell lines treated with increasing doses of hydroxyurea, with foci intensity correlating with treatment dose . Second, implement rigorous antigen retrieval methods to counteract epitope masking caused by formalin fixation – heat-induced epitope retrieval in citrate or EDTA buffer is typically effective for phospho-epitopes. Third, optimize antibody concentration through titration experiments, typically starting at manufacturer-recommended dilutions and adjusting as needed for FFPE samples specifically. Fourth, include appropriate controls in each staining batch: positive controls (hydroxyurea-treated cell blocks), negative controls (RPA2 knockdown samples), and technical controls (no primary antibody) . Fifth, when evaluating tumor samples, have a board-certified pathologist screen specimens for diagnosis, cellularity, and necrosis to ensure sample quality . Sixth, address tumor heterogeneity by analyzing more than 100 cells per sample, with a standardized scoring system (e.g., percentage of cells with ≥5 pRPA2 foci) . Through these optimizations, researchers have successfully established pRPA2 detection in FFPE samples as both sensitive and specific, accurately reflecting replication stress levels and enabling clinically relevant predictions of therapy response in cancer patients .

What are the key differences between basic and hyperphosphorylated forms of RPA2?

The basic (unphosphorylated or basally phosphorylated) and hyperphosphorylated forms of RPA2 differ substantially in several aspects: First, molecular weight and electrophoretic mobility – hyperphosphorylated RPA2 displays a higher apparent molecular weight of approximately 40 kDa on western blots compared to the basic form at 32-34 kDa due to the addition of multiple phosphate groups . Second, phosphorylation sites – the basic form has minimal phosphorylation, while the hyperphosphorylated form contains phosphorylated residues at multiple sites including threonine 21 and serines 4, 8, 23, 29, and 33 in the N-terminal domain . Third, cellular localization – while both forms can be nuclear, hyperphosphorylated RPA2 forms distinct nuclear foci at sites of DNA damage and stalled replication forks, which can be visualized by immunofluorescence . Fourth, protein interactions – hyperphosphorylated RPA2 demonstrates increased affinity for the recombination protein Rad51 compared to the basic form, facilitating homologous recombination repair . Fifth, cellular function – basic RPA2 primarily supports normal DNA replication, while hyperphosphorylated RPA2 inhibits further DNA replication and promotes DNA repair pathways . Sixth, cell cycle distribution – hyperphosphorylation of RPA2 occurs predominantly in late S and G2 phases, particularly in response to replication stress, whereas the basic form is present throughout the cell cycle . Understanding these differences is crucial for correctly interpreting experimental results and evaluating the physiological significance of RPA2 phosphorylation in different biological contexts.

How do different DNA-damaging agents affect RPA2 phosphorylation patterns?

Different DNA-damaging agents induce distinct RPA2 phosphorylation patterns due to their varied mechanisms of action: Hydroxyurea (HU) inhibits ribonucleotide reductase, leading to DNA synthesis arrest and eventual double-strand breaks after prolonged treatment (>12 hours), resulting in robust RPA2 hyperphosphorylation including at T21 . This phosphorylation pattern is closely associated with stalled replication forks and subsequent fork collapse. Thymidine (Thy) disrupts DNA synthesis by altering the balance between thymidine triphosphate and deoxycytidine triphosphate through allosteric inhibition of ribonucleotide reductase, also inducing RPA2 phosphorylation patterns similar to hydroxyurea but without generating detectable double-strand breaks in short-term treatments . Camptothecin (CPT), a topoisomerase I inhibitor, generates replication-dependent DNA damage and strongly induces RPA2 hyperphosphorylation including at T21, as demonstrated in HeLa and U2OS cells . Ionizing radiation (IR) directly causes DNA double-strand breaks independent of replication and induces RPA2 phosphorylation patterns distinct from replication inhibitors, with cells expressing phosphorylation-defective RPA2 showing similar sensitivity to IR as wild-type cells . These agent-specific phosphorylation patterns reflect the different mechanisms of DNA damage and repair pathway activation. For experimental design, researchers should select DNA-damaging agents based on the specific aspect of DNA damage response they wish to study, with replication inhibitors like hydroxyurea being most appropriate for investigating RPA2's role in replication stress response .

How can phospho-RPA2-T21 be integrated with other biomarkers for personalized cancer treatment?

Phospho-RPA2-T21 shows significant promise for integration with other biomarkers to guide personalized cancer treatment decisions. Recent research has demonstrated that combining phospho-RPA2-T21 (pRPA2) with RAD51 assessment creates a powerful predictive tool for therapy response . Specifically, tumors can be categorized into distinct groups: RAD51-Low (HR-deficient), RAD51-High/pRPA2-High, and RAD51-High/pRPA2-Low, each with different therapeutic implications . RAD51-Low tumors respond well to platinum chemotherapy and PARP inhibitors due to homologous recombination deficiency. RAD51-High/pRPA2-High tumors, despite being HR-proficient, also respond favorably to platinum chemotherapy and potentially to PARP inhibitors due to endogenous replication stress. RAD51-High/pRPA2-Low tumors show resistance to both platinum chemotherapy and PARP inhibitors . This integrated approach addresses a critical clinical challenge: identifying which HR-proficient tumors will respond to standard therapies. The combined RAD51/pRPA2 assay can be performed on FFPE samples and shows dynamic properties, allowing for real-time evaluation of tumor behavior in response to therapy . Future directions include prospective clinical validation of this combined biomarker approach, potentially expanding the panel to include additional replication stress markers such as ATR pathway activation indicators. Another promising avenue involves using this biomarker profile to identify patients who might benefit from combination therapies, such as adding replication stress-inducing agents (e.g., gemcitabine) to standard platinum chemotherapy, particularly for patients with pRPA2-Low tumors .